This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
News|Podcasts|April 17, 2026
Strategic Operations, Manufacturing and Supply Chain Resilience
Author(s)Avantor, Inc.
BioPharm International sat down with Mary Blenn, Executive Vice President and Chief Operating Officer at Avantor, to discuss how superior manufacturing and supply chain performance are key to delivering a consistently exceptional customer experience. Blenn walks us through strategic investment strategies in capabilities and operational design. These initiatives validate how modernized ways of working translate into better reliability, faster delivery, higher quality and more predictable performance for customers across the globe.
Learning Objectives:
- Understand how targeted investments in manufacturing and supply chain strengthen reliability, quality and long-term value for customers.
- Learn the key to balancing operations that support an “in-region, for-region” model while remaining agile enough to meet customer needs at speed and scale.
- Highlight best practices to accelerate the adoption of standardizations and efficiencies across a global network.
Related to this article
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
In the second part of an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 414 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Trending on BioPharm International
1
Iovance’s Lifileucel Reaches 52% Response Rate in Biomarker-Selected Lung Cancer Subgroup
2
Genmab’s Petosemtamab Plus Pembrolizumab Cuts Risk of Death by 50% in Phase 3 Head and Neck Cancer Trial
3
The BioPharm Brief: A Psoriatic Arthritis Approval, a Subcutaneous Fabry Bet, and ADC Capacity
4
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
5